ArticleAmerican journal of translational research2025
Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of different initiation times of capecitabine metronomic chemotherapy on prognosis and safety in patients with early-stage triple-negative breast cancer (TNBC).
methodsThis retrospective study included 206 early-stage TNBC patients treated between March 2018 and January 2022. The patients were divided into early (≤ 4 weeks after surgery, n = 104) and delayed (> 4 weeks, n = 102) initiation groups. Clinical data, laboratory indicators (carcinoembryonic antigen [CEA], carbohydrate antigen 125 [CA125], neutrophil-to-lymphocyte ratio [NLR]), survival, and adverse reactions were compared between the two groups.
resultsThe early initiation group showed significantly longer 3-year progression-free survival (PFS) (P < 0.05) but similar overall survival (OS) (P > 0.05). Reductions in CEA, CA125, and NLR were more prominent in the early initiation group (P < 0.05). Subgroup analysis indicated a PFS advantage for T2-stage patients. Adverse reactions, mainly hand-foot syndrome and bone marrow suppression, were comparable between groups, with most cases being grade 1-2.
conclusionEarly initiation of capecitabine metronomic chemotherapy can improve the PFS in early-stage TNBC patients, especially for patients with T2 stage, with manageable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.